APLS Q1 2025 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$167M-3.2% YoY

Gross Profit

$132M79.4% margin

Operating Income

-$83M-50.0% margin

Net Income

-$92M-55.3% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-21.5%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$53M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$807M

Total Liabilities

$643M

Stockholders' Equity

$164M

Cash & Equivalents

$358M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$167M	$172M	-3.2%
Gross Profit	$132M	$152M	-12.7%
Operating Income	-$83M	-$62M	-34.2%
Net Income	-$92M	-$66M	-38.8%

Revenue Segments

Product

$150M90%

Licensing And Other Revenue

$17M10%